Multisite phosphorylation regulates many transcription factors, including the serum response factor partner Elk-1. Phosphorylation of the transcriptional activation domain (TAD) of Elk-1 by the protein kinase ERK at multiple sites potentiates recruitment of the Mediator transcriptional coactivator complex and transcriptional activation, but the roles of individual phosphorylation events had remained unclear. Using time-resolved nuclear magnetic resonance spectroscopy, we found that ERK2 phosphorylation proceeds at markedly different rates at eight TAD sites in vitro, which we classified as fast, intermediate, and slow. Mutagenesis experiments showed that phosphorylation of fast and intermediate sites promoted Mediator interaction and transcriptional activation, whereas modification of slow sites counteracted both functions, thereby limiting Elk-1 output. Progressive Elk-1 phosphorylation thus ensures a self-limiting response to ERK activation, which occurs independently of antagonizing phosphatase activity.
M
ultisite protein phosphorylation increases the complexity of functional signaling outputs that can be generated from single protein kinase inputs. It can set thresholds for activity or transform graded signals into switch-like responses (1) (2) (3) (4) . Many transcription factors and their interacting regulatory proteins are subject to multisite phosphorylation, which allows distinct aspects of protein functionincluding protein turnover, nuclear import and export, and specific protein interactions-to be controlled independently (5) . However, in general, the dynamics and functional roles of individual phosphorylation events are incompletely understood.
The ternary complex factor (TCF) subfamily of Ets-domain transcription factors, consisting of Elk-1, SAP-1, and Net, provides an example of multisite phosphorylation in transcriptional activation. TCFs, together with their partner protein SRF, function in many biological processes by coupling SRF target genes to mitogen-activated protein kinase (MAP kinase) signaling (5) . Mitogenic and stress stimuli induce phosphorylation of TCF C-terminal transcriptional activation domains (TADs) at multiple S/T-P (Ser or Thr-Pro) phosphorylation sequences, of which eight are conserved across the family (Fig. 1A and fig. S1 ) (6) (7) (8) (9) (10) (11) . Two MAP kinase docking sites, the D-box and the Phe-Gln-Phe-Pro (FQFP) motif, control phosphorylation of these sites (12) (13) (14) (15) . Multisite phosphorylation triggers transcriptional activation by TCFs, facilitating their interaction with the Mediator transcriptional coactivator complex (16) (17) (18) (19) , but the kinetics with which the different sites are phosphorylated, and whether they serve distinct functions, remain unclear.
To obtain atomic-resolution insights into phosphorylation of the Elk-1 TAD, we used nuclear magnetic resonance (NMR) spectroscopy (20) to monitor its modification by recombinant ERK2 in vitro (Fig. 1B and fig. S2A , and Thr 337 were modified more slowly (Fig. 1C) , which we confirmed by immunoblotting (Fig. 1D) Fig. 2A and  fig. S3A ) (20) . This model, which recapitulated the measured kinetics of in vitro Elk-1 phosphorylation well (Fig. 2B) (Fig. 2A) . In the fast-site mutant Elk-1F, phosphorylation rates of intermediate and slow sites increased, whereas those of the fast and slow sites increased in the intermediate-site mutant Elk-1I; in both cases, the altered kinetics fit well with those predicted by the model (Fig. 2B and fig.  S3B , with no effect on the C-terminal sites (Fig. 2D) . Thus, the ERK docking motifs differentially affect each phosphorylation site's competitive behavior. Previous studies showed that Elk-1 TAD phosphorylation by JNK and p38 MAP kinases differs from phosphorylation by ERK (10, 21-24) and that this reflects differences in their docking interactions (12, 14, 15, 25) . Indeed, these kinases exhibited site preferences and phosphorylation rates that were distinct from that of ERK2 ( fig. S3C ). Taken together, our results show that the different rates of Elk-1 TAD phosphorylation by ERK2 follow a competition mechanism that is governed by the position of individual Elk-1 substrate sites relative to ERK2 docking interactions.
To test whether the different kinetic classes of Elk-1 TAD phosphorylation sites are functionally equivalent, we expressed Elk-1 mutants in fibroblasts derived from TCF-deficient (Elk1 (Fig. 3A) . Surprisingly, however, mutation of the slow sites substantially enhanced Elk-1-mediated activation of TCF-SRF target genes (Fig. 3A) . Alanine substitutions at individual slow sites also increased Elk-1 activity, with Thr 418 exhibiting the greatest effect ( Fig. 3B  and fig. S4 , E to G). TCF-SRF signaling is important for cellular proliferation (26, 27) , and TKO MEFs proliferated more slowly than wild-type MEFs. The reconstituted TKO MEFs exhibited enhanced proliferation rates, which correlated with the ability of each mutant to promote transcriptional activation (Fig. 3C) .
Phosphorylation of Elk-1 promotes transcriptional activation by facilitating its MED23-dependent interaction with the Mediator complex (16) (17) (18) . We therefore investigated whether the different transcriptional activities of the Elk-1 mutants reflected alterations in Mediator binding. We prepared extracts of TKO cells expressing wild-type or mutant Elk-1 proteins and assessed Elk-1 association with Mediator by coimmunoprecipitation of the MED23, MED24, and MED16 subunits. Consistent with the transcription experiments, Elk-1-Mediator interaction was induced by TPA stimulation and dependent on the FW motif; it was abolished by alanine substitutions of fast and intermediate sites, and increased in the slow-site Elk-1 mutant (Fig. 3D) . We obtained similar results when we used glutathione S-transferase (GST)-Elk-1 TAD proteins to recover Mediator proteins from unstimulated NIH3T3 cell extracts (Fig. 3E) . In this assay, ERK2 phosphorylation time-course experiments showed that Mediator recovery by the wild-type Elk-1 TAD was most efficient prior to modifications of the slow sites ( fig. S5, A and B) . Taken together, these data show that according to the sites involved, ERK2 phosphorylation promotes or inhibits transcriptional activation by Elk-1, which reflects alterations in Elk-1-Mediator interactions.
Next, we investigated Elk-1 TAD phosphorylation kinetics in vivo. Previous studies were unable to distinguish the progressive phosphorylation of fast and slow Elk-1 sites (6). However, by incubating cells at 25°C to slow down reactions, we confirmed that phosphorylation rates can be ranked in the order Ser 384 > Thr 364 > Thr 418 and that different site classes exhibited a similar competitive behavior, as seen in vitro ( fig. S6A ). Reasoning that phosphorylation of the Elk-1 TAD might be sensitive to kinetic effects at limiting signal strengths, we titrated ERK activity using ) modifications accumulated slowly over 1 hour, whereas at a saturating TPA dose they were maximal by 10 min. Both phosphorylations declined at late times, presumably owing to the action of Elk-1 phosphatases (Fig. 4A) (6, 28) .
Having established that Elk-1 phosphorylation kinetics are tuned by signal strength, we investigated their relationship to transcriptional activation. We compared the ability of wild-type Elk-1 and the slow-site mutant Elk-1S to activate transcription in response to signals of differing strengths. At saturating TPA concentrations, both proteins activated Egr1 transcription with similar transient kinetics, although Elk-1S was much more active, reflecting the loss of the inhibitory sites (Fig. 4, B and C) . At limiting TPA doses, however, their behaviors were markedly different. Whereas the activity of wild-type Elk-1 was almost maximal by 15 min, that of Elk-1S increased substantially beyond this time (Fig. 4B) , resulting in prolonged Egr1 mRNA accumulation (Fig. 4C) . Thus, progressive phosphorylation of the Elk-1 TAD by a single kinase, ERK, attenuates the transcriptional response of Elk-1, shaping it according to the strength and kinetics of ERK activation.
Our results show that phosphorylation of the Elk-1 TAD by ERK can either promote or inhibit Mediator interaction depending on the sites involved, thereby modulating transcriptional activation. Given that the TAD sequences are conserved in the other TCFs, our findings may also apply to them. The more rapidly phosphorylated sites are located in the substantially conserved central core of the TAD and are essential for transcriptional activation, lying close to the FW hydrophobic motif required for Elk-1-Mediator interaction (10, 18) . Multisite phosphorylation of these residues might stabilize this interaction and perhaps also set a signaling threshold for it, similar to the way that multisite phosphorylation sets a threshold for the Sic1-Cdc4 interaction (29) . In contrast, slowly phosphorylated sites located Nand C-terminal of the conserved TAD core act negatively. Their phosphorylation inhibits Mediator recruitment and limits transcriptional activation (Fig. 4D) and may also facilitate recruitment of negative regulators of Elk-1 activity. Together, these properties ensure that ERK phosphorylation of the Elk-1 TAD is self-limiting, whereby phosphorylation of slow sites attenuates TCF-SRF target gene expression under conditions of strong or sustained ERK signaling (Fig. 4D) . Our results challenge the common assumption that multisite modification events act unidirectionally and can only be reversed or limited by antagonistic enzymes, such as phosphatases. Given the prevalence of such events in different biological processes, we expect that similar mechanisms may govern other regulatory interactions. designed, executed, and interpreted the NMR experiments; and A.M., P.S., and R.T. designed and interpreted experiments and wrote the paper. We thank F. Gualdrini, C. Esnault, and P. Zika virus (ZIKV) was identified as a cause of congenital disease during the explosive outbreak in the Americas and Caribbean that began in 2015. Because of the ongoing fetal risk from endemic disease and travel-related exposures, a vaccine to prevent viremia in women of childbearing age and their partners is imperative. We found that vaccination with DNA expressing the premembrane and envelope proteins of ZIKV was immunogenic in mice and nonhuman primates, and protection against viremia after ZIKV challenge correlated with serum neutralizing activity. These data not only indicate that DNA vaccination could be a successful approach to protect against ZIKV infection, but also suggest a protective threshold of vaccineinduced neutralizing activity that prevents viremia after acute infection.
T he emergence of Zika virus (ZIKV) in the Americas and Caribbean follows a series of global threats to public health from mosquito-borne viral diseases over the past three decades. Because of the profound impact on individuals and society from a disabling congenital disease caused by ZIKV infection in pregnant women, the World Health Organization declared ZIKV a global health emergency in February 2016. Although it is likely that the incidence of ZIKV infection will decline considerably within 1 to 2 years (1), it is also likely that ZIKV will become endemic in tropical and subtropical regions, with sporadic outbreaks and potential for spread into new geographical areas, as observed with other emerging arboviruses such as West Nile (WNV) and chikungunya. Therefore, unless immunity is established before childbearing age, pregnant women will continue to be at risk for an infection that could harm their fetus. Further, because men can harbor ZIKV in semen for several months after a clinically unapparent infection and can sexually transmit virus to a pregnant partner (2), even women in nonendemic regions will have some ongoing risk if exposed to men who have traveled to endemic regions. These characteristic features of transmission and disease suggest that there will be an ongoing need for a ZIKV vaccine to maintain a high level of immunity in the general population and in travelers to endemic regions to reduce the frequency of fetal infection.
To rapidly address the critical need for a preventive vaccine to curtail the ongoing ZIKV outbreak in the Americas, we chose a gene-based vaccine delivery approach that leverages our prior experience with a DNA-based WNV vaccine (3). Advantages of DNA vaccines include the ability to rapidly test multiple candidate antigen designs, the ability to rapidly produce material that conforms to good manufacturing practices, an established safety profile in humans, and a relatively straightforward regulatory pathway into clinical evaluation.
Antigen design was guided by prior knowledge about humoral immunity to flaviviruses. Vaccineelicited neutralizing antibodies (NAbs) are associated with protection from flavivirus-mediated disease (4) . Because the most potent monoclonal flavivirus NAbs map to conformational epitopes in domain III (DIII) of the envelope (E) protein (5), or to more complex quaternary epitopes that bridge between antiparallel E dimers or between dimer rafts arrayed on the virus surface (6, 7), our goal was to identify constructs that produced particles that faithfully captured the antigenic complexity of infectious virions. Expression of the structural proteins premembrane (prM) and E are sufficient for the production and release of virus-like subviral particles (SVPs) with antigenic and functional properties similar to those of infectious virions (8, 9) .
To identify promising vaccine candidates, prM-E constructs were synthesized and screened for expression and efficiency of particle release from transfected cells. prM-E sequences were inserted into a cytomegalovirus immediate early promotercontaining vector (VRC8400) that has been evaluated clinically in several previous studies (3, 10, 11) . These constructs are distinct from one reported in recent studies by Larocca et al. (12) and Abbink et al. 
